

# Do patients undergoing coronary artery bypass grafting benefit from concomitant mitral valve surgery?

<b>Submission date</b> 10/03/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 28/06/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 28/06/2011	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Denis Bouchard

**Contact details**  
Montreal Heart Institute  
Rue Belanger 5000  
Montreal  
Canada  
H1T 1C8  
andre.denis.bouchard@gmail.com

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**  
Moderate functional ischemic mitral regurgitation patients randomised to Coronary Artery Bypass Graft (CABG) versus CABG and down-sized ring annuloplasty

**Study objectives**

In patients with moderate functional ischemic mitral regurgitation, CABG combined with down-sized mitral ring annuloplasty improves freedom from persistent or recurrent mitral regurgitation compared with CABG alone

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Committee of Research Ethics and Development of New Technologies, Montreal Heart Institute, Montreal, Qc, Canada. 2 May 2002, ref: CÉRDNT 01-087

**Study design**

Randomised controlled study

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Functional ischemic mitral regurgitation

**Interventions**

1. Intervention group: Coronary artery bypass grafting + down-sized mitral ring annuloplasty
2. Control group: Coronary artery bypass grafting
3. Follow-up: Echocardiography 6 months, 1 year

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

1. Mitral regurgitation severity
2. Left ventricular geometry and function
3. Evaluated 6 and 12 months by echocardiography

**Key secondary outcome(s)**

1. Mortality: in hospital and 5 years
2. New York Heart Association (NYHA) class: evaluated at 5 years
3. The following outcomes are measured 12 months postop
  - 3.1. 6-min walk test
  - 3.2. Minnesota questionnaire score
  - 3.3. Brain Natriuretic Peptide (BNP)

**Completion date**

01/07/2011

# Eligibility

## Key inclusion criteria

Moderate (grade 2+) functional ischemic mitral regurgitation in patients undergoing coronary artery bypass grafting

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Adult

## Sex

All

## Key exclusion criteria

1. Papillary muscle rupture
2. Concomitant aortic valve surgery
3. Life expectancy less than 12 months
4. Creatinine > 200 µmol/l

## Date of first enrolment

28/06/2002

## Date of final enrolment

01/07/2011

# Locations

## Countries of recruitment

Canada

## Study participating centre

**Montreal Heart Institute**

Montreal

Canada

H1T 1C8

# Sponsor information

## Organisation

Montreal Heart Institute (Canada)

**ROR**

<https://ror.org/03vs03g62>

## **Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

Montreal Heart Institute, Quebec (Canada)

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration